Article
Oncology
Yujia Zheng, Hao Zhang, Chu Xiao, Ziqin Deng, Tao Fan, Bo Zheng, Chunxiang Li, Jie He
Summary: The expression of KLF12 in tumors is correlated with resistance to immunotherapy. KLF12 suppresses the infiltration and function of CD8(+) T cells by inhibiting the expression of Gal-1. Targeting the KLF12/Gal-1 pathway may provide a new therapeutic target for patients with immunotherapy resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
Weizhen Jia, Lingyu Kong, Hiroyasu Kidoya, Hisamichi Naito, Fumitaka Muramatsu, Yumiko Hayashi, Han-Yun Hsieh, Daishi Yamakawa, Daniel K. Hsu, Fu-Tong Liu, Nobuyuki Takakura
Summary: This study demonstrates that Gal-3 expression in long-term repopulating HSCs is induced in response to Tie2 and Mpl, and plays a crucial role in maintaining HSC quiescence through regulation of p21.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Jiang Liu, Degan Liu, Guangyin Hu, Jingjing Wang, Dadong Chen, Chuanjun Song, Yin Cai, Chentong Zhai, Wenjing Xu
Summary: This study investigated the predictive values of circulating CD8(+) T cells and CD8(+)T/CD4(+)T cell ratio in advanced gastric cancer patients receiving immunotherapy. The results showed that patients with higher percentages of CD8(+) T and CD8(+) Tm expressing PD-1, as well as a higher PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio, had better survival outcomes. These findings provide preliminary evidence for screening the population that would benefit from immunotherapy.
CANCER CELL INTERNATIONAL
(2023)
Article
Multidisciplinary Sciences
Alejandro J. Cagnoni, Maria Laura Giribaldi, Ada G. Blidner, Anabela M. Cutine, Sabrina G. Gatto, Rosa M. Morales, Mariana Salatino, Martin C. Abba, Diego O. Croci, Karina V. Marino, Gabriel A. Rabinovich
Summary: Colorectal cancer is a common malignancy with limited response to immunotherapy, prompting the need for new biomarkers and therapeutic targets. Gal-1, as an endogenous glycan-binding protein, has been found to influence the activity of CD8(+) regulatory T cells in CRC, suggesting a potential immunotherapeutic approach for this disease.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Immunology
Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slack
Summary: This study found that Gal-3 can enhance the PD-1/PD-L1 immune axis and potentially contribute to immunosuppressive signaling mechanisms within the tumor microenvironment. Additionally, Gal-3 prevents atezolizumab and pembrolizumab from engaging with their respective immune checkpoint receptors. Reversal of this effect with the clinical candidate GB1211 offers a potential enhancing combination therapeutic with anti-PD-1 and -PD-L1 blocking antibodies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Elisa Ciraolo, Stefanie Althoff, Josefine Russ, Stanislav Rosnev, Monique Butze, Miriam Puhl, Marco Frentsch, Lars Bullinger, Il-Kang Na
Summary: This study explores the combination of T cell immunotherapy and genetic disruption of checkpoint molecule expression in the treatment of solid tumors, leading to improved efficacy and safety.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Julie Niogret, Helene Berger, Cedric Rebe, Romain Mary, Elise Ballot, Caroline Truntzer, Marion Thibaudin, Valentin Derangere, Christophe Hibos, Lea Hampe, David Rageot, Theo Accogli, Philippe Joubert, Bertrand Routy, James Harker, Frederique Vegran, Francois Ghiringhelli, Fanny Chalmin
Summary: Tfh cells play an important role in antitumor immune response, especially in a CD8(+)-dependent manner, by producing interleukin-21 to support the function of exhausted T cells. Their accumulation in tumor sites and draining lymph nodes is closely associated with treatment efficacy and patient survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Rui Qin, Chen Zhao, Chen-Ji Wang, Wei Xu, Jian-Yuan Zhao, Yan Lin, Yi-Yuan Yuan, Peng-Cheng Lin, Yao Li, Shimin Zhao, Yan Huang
Summary: This study demonstrated that IDO inhibitors activate CD8(+) T cells by increasing tryptophan levels and consequently downregulating PD-1 expression. Tryptophan and IDO inhibitors both potentiate CD8(+) T cells to induce apoptosis of cancer cells through different mechanisms, suggesting a potential synergistic effect in anticancer treatments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Brendan D. Curti, Yoshinobu Koguchi, Rom S. Leidner, Annah S. Rolig, Elizabeth R. Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B. Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G. Traber, Eliezer Zomer, J. Rex Horton, Harold Shlevin, William L. Redmond
Summary: Combination therapy of belapectin and pembrolizumab shows promising activity in patients with metastatic melanoma and head and neck squamous cell carcinoma, with increased activation of effector memory T cells and decreased levels of monocytic myeloid-derived suppressor cells observed in responders. Additionally, increased expression of Gal-3, PD-1+CD8+ T cells, and higher serum trough levels of pembrolizumab are correlated with treatment response, indicating potential biomarkers for clinical outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Jiajia Ma, Shufang Yan, Ying Zhao, Huifang Yan, Qian Zhang, Xinxia Li
Summary: LAG-3 and PD-1 gene expression levels are significantly up-regulated in DLBCL tissues. Combined blockade of LAG-3 and PD-1 can restore CD8+ T cell function and provide a potential avenue for the development of personalized cellular immunotherapy for DLBCL.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Joan Choo, Ley Fang Kua, Mu Yar Soe, Bernadette Reyna Asuncion, Benjamin Kye Jyn Tan, Chong Boon Teo, Ryan Yong Kiat Tay, Jimmy So, Asim Shabbir, Kim Guowei, Hon Lyn Tan, Gloria Chan, Haoran Ma, Gokula Krishnan Ramachandran, Jeffrey H. Y. Lum, Cheng Ean Chee, Sriram Sridharan, Patrick Tan, Raghav Sundar, Wei Peng Yong
Summary: PD-1(+)CD8(+) T-cells in gastric cancer are associated with prognosis, chemotherapy and immunotherapy sensitivity, and tumor microenvironment. Tumors with high PD-1 and CD8A expression levels show improved overall survival with immunotherapy and chemotherapy. CD8PD-1(high) tumors have an immunologically active, T-cell inflamed tumor microenvironment.
Article
Immunology
An-Liang Guo, Jin-Fang Zhao, Lin Gao, Hui-Huang Huang, Ji-Yuan Zhang, Chao Zhang, Jin-Wen Song, Ruo-Nan Xu, Xing Fan, Ming Shi, Yan-Mei Jiao, Fu-Sheng Wang
Summary: The study found that CD11c(+) CD8(+) T cells can effectively control viral replication during HIV-1 infection and have the potential to be used as an immunotherapeutic approach.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Siyu Liu, Chang Xu, Fan Yang, Lu Zong, Yizu Qin, Yufeng Gao, Qian Su, Tuantuan Li, Ye Li, Yuanhong Xu, Meijuan Zheng
Summary: The antiviral response of NK cells and CD8(+) T cells is weak in patients with CHB, and the overexpression of Gal-9 contributes to NK cell dysfunction and CD8(+) T cell exhaustion. Blocking Gal-9 or TIM-3 can restore the function of CD8(+) T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Marie Le Moine, Abdulkader Azouz, Guillem Sanchez Sanchez, Solange Dejolier, Muriel Nguyen, Severine Thomas, Valdrin Shala, Hacene Dreidi, Sebastien Denanglaire, Frederick Libert, David Vermijlen, Fabienne Andris, Stanislas Goriely
Summary: The co-inhibitory programmed death (PD)-1 signaling pathway has a crucial role in tumor-specific T cell responses as well as peripheral tolerance. This study reveals the involvement of PD-1 signaling in liver memory T cell homeostasis through the preferential expansion of CD8+ T cells with oligoclonal TCR repertoire and terminally differentiated exhaustion profile. The transcription factor EOMES is found necessary for the clonal expansion and acquisition of this differentiation program.
Article
Immunology
Amalie Skak Scholler, Loulieta Nazerai, Jan Pravsgaard Christensen, Allan Randrup Thomsen
Summary: The expression of PD-1 within the CNS correlates with decreased severity of clinical disease and is associated with local antigen encounter, despite its link to increased infiltration of CD8(+) T cells and upregulation of PD-L1 expression levels. Furthermore, despite the expression of markers associated with T-cell exhaustion, CNS Trms cells showed no signs of limited effector capacity.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.